Houston, TX October 10, 2024’ Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company focused on developing biologics to enhance regulatory T cell (Treg) function, has several exciting announcements that promise to impact the landscape of neurological disease treatment profoundly.
Groundbreaking Alzheimer’s Disease Study Results to be Presented at CTAD24
Coya Therapeutics has revealed that the results from a rigorous double-blind, placebo-controlled phase 2 clinical trial of interleukin-2 (IL-2) in patients with mild to moderate Alzheimer’s Disease will be showcased on October 29, 2024, at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid. This significant study, conducted in collaboration with Houston Methodist Research Institute and supported by the Gates Foundation and the Alzheimer’s Association, targets harnessing IL-2 to enhance Treg function, which may offer new therapeutic pathways for Alzheimer’s Disease.
The CEO of Coya Therapeutics, Dr. Howard Berman, expressed his enthusiasm, stating, “The forthcoming presentation of our Alzheimer’s clinical trial data at CTAD24 represents an essential milestone for Coya Therapeutics. We are dedicated to exploring innovative treatments targeting the immunological aspects of neurodegenerative diseases, and we believe IL-2 has the potential to make a substantial impact on how Alzheimer’s Disease is treated in the future.”
Publication of ALS Study in Frontiers in Neurology
Coya Therapeutics has also garnered attention in the scientific community following the publication of their peer-reviewed manuscript
Comments